Catherine Psaras

Dec 3, 2023 | ophthalmologyscience.org | Jeremy Keenan |Catherine Psaras |Christina J. Flaxel

ABSTRACTMetformin use has been associated with a decreased risk of age-related macular degeneration (AMD) progression in observational studies. We aimed to evaluate the efficacy of oral metformin for slowing geographic atrophy (GA) progression. Parallel-group, multicenter, randomized phase 2 clinical trial. Participants aged at least 55 years without diabetes who had GA from atrophic AMD in at least 1 eye.